Evidence map›Paper›PMID 39835149›Full record

ArticleFrontiers in neurology2024

Retrospective analysis of amantadine response and predictive factors in intensive care unit patients with non-traumatic disorders of consciousness.

Corinna Blum, Constanze Single, Kornelia Laichinger, Anna Hofmann, Tim W Rattay, Kamaldeen Adeyemi, Reimer Riessen, Michael Haap, Helene Häberle, Ulf Ziemann and 2 more

Abstract read
In one paragraph

Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Corinna BlumDepartment of Neurology & Stroke, University Hospital Tübingen, Tübingen, Germany.
Constanze SingleDepartment of Neurology & Stroke, University Hospital Tübingen, Tübingen, Germany.
Kornelia LaichingerDepartment of Neurology & Stroke, University Hospital Tübingen, Tübingen, Germany.
Anna HofmannDepartment of Neurology/Neurodegenerative Diseases, University Hospital Tübingen, Tübingen, Germany.
Tim W RattayDepartment of Neurology & Stroke, University Hospital Tübingen, Tübingen, Germany.
Kamaldeen AdeyemiDepartment of Neurology & Stroke, University Hospital Tübingen, Tübingen, Germany.
Reimer RiessenDepartment for Internal Medicine, University Hospital Tübingen, Tübingen, Germany.
Michael HaapDepartment for Internal Medicine, University Hospital Tübingen, Tübingen, Germany.
Helene HäberleDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Tübingen, Tübingen, Germany.
Ulf ZiemannDepartment of Neurology & Stroke, University Hospital Tübingen, Tübingen, Germany.
Annerose Mengel *Department of Neurology & Stroke, University Hospital Tübingen, Tübingen, Germany.
Katharina Feil *Department of Neurology & Stroke, University Hospital Tübingen, Tübingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Disorders of consciousness (DoC) in non-traumatic ICU-patients are often treated with amantadine, although evidence supporting its efficacy is limited. Methods: This retrospective study analyzed non-traumatic DoC-patients treated with amantadine between January 2016 and June 2021. Data on patient demographics, clinical characteristics, treatment specifications, and outcomes were extracted from electronic medical records. Patients were classified as responders if their Glasgow Coma Scale (GCS) improved by ≥3 points within 5 days. Good outcome was defined as a modified Rankin Scale (mRS) of 0-2. Machine learning techniques were used to predict response to treatment. Results: Of 442 patients (mean age 73.2 ± 10.7 years, 41.0% female), 267 (60.4%) were responders. Baseline characteristics were similar between groups, except that responders had lower baseline GCS (7 [IQR 5-9] vs. 8 [IQR 5-10], Conclusion: This study supports the potential benefits of intravenous amantadine in non-traumatic DOC-patients. Higher premorbid mRS, and pathological cerebral imaging were key predictors of non-response, offering potential avenues for patient selection and treatment customization. Findings from this study informed the design of our ongoing prospective study, which aims to further evaluate the long-term efficacy of amantadine.

Indexed as

adverse eventsamantadinedisorders of consciousnessfunctional recoveryneurointensive carenon-traumatic brain disordersresponse profileretrospective analysis

Identifiers

PMID39835149
PMCPMC11743167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.